BR9814075A - Método de tratamento da doença de alzheimer - Google Patents

Método de tratamento da doença de alzheimer

Info

Publication number
BR9814075A
BR9814075A BR9814075-2A BR9814075A BR9814075A BR 9814075 A BR9814075 A BR 9814075A BR 9814075 A BR9814075 A BR 9814075A BR 9814075 A BR9814075 A BR 9814075A
Authority
BR
Brazil
Prior art keywords
carbon atoms
hydrogen
lower alkyl
alzheimer
treatment
Prior art date
Application number
BR9814075-2A
Other languages
English (en)
Inventor
David Robert Howlett
Davina Elizabeth Mitchell
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Publication of BR9814075A publication Critical patent/BR9814075A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODO DE TRATAMENTO DA DOENçA DE ALZHEIMER" Método de tratamento ao usar a fórmula (I): onde R~ 7~ - R~ 13~ são independentemente -H ou -OH; e A é H ou uma parcela de fórmula (II), onde R~ 1~ é hidrogênio, alcanoila inferior de cerca de 6 átomos de carbono ou aroíla selecionada a a partir de benzoíla e naftoíla; R~ 2~ é hidrogênio, alquila inferior de cerca de 6 átomos de carbono ou arilalquila selecionada a partir de benzila, feniletila e fenilpropila; R~ 3~ é hidrogênio ou alquila inferior de cerca de 6 átomos de carbono, R~ 4~ é hidrogênio ou alquila inferior de cerca de 6 átomos de carbono, ou quando X é oxigênio, R~ 4~ junto com R~ 5~ pode representar -CH~ 2~-O; X é uma ligação de valência, -CH~ 2~, oxigênio ou enxófre, Ar é selecionado entre fenila, naftila, indanila e tetrahidronaftila; R~ 5~ e R~ 6~ são individualmente selecionados entre hidrogênio, flúor, bromo, hidroxila, alquila inferior de cerca de 6 átomos de carbono, um grupo -CONH~ 2~-, alcóxi inferior de cerca de 6 átomos de carbono, benzilóxi, alquiltio inferior de cerca de 6 átomos de carbono, alquilsulfinila inferior de cerca de 6 átomos de carbono e alquilsulfonila inferior de cerca de 6 átomos de carbono; ou R~ 5~ e R~ 6~ juntos representam metilenodióxi, ou um sal farmaceuticamente aceitável do mesmo para o tratamento de doenças amilóides e, assim, dotado de utilidade no tratamento da doença de Alzheimer.
BR9814075-2A 1997-10-15 1998-10-15 Método de tratamento da doença de alzheimer BR9814075A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6236697P 1997-10-15 1997-10-15
PCT/US1998/021789 WO1999018794A1 (en) 1997-10-15 1998-10-15 Method for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
BR9814075A true BR9814075A (pt) 2000-09-26

Family

ID=22042015

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814075-2A BR9814075A (pt) 1997-10-15 1998-10-15 Método de tratamento da doença de alzheimer

Country Status (16)

Country Link
US (1) US6358990B1 (pt)
EP (1) EP1024697A4 (pt)
JP (1) JP2001519364A (pt)
KR (1) KR100573352B1 (pt)
CN (1) CN1281334A (pt)
AU (1) AU751526B2 (pt)
BR (1) BR9814075A (pt)
CA (1) CA2305262A1 (pt)
HU (1) HUP0100024A3 (pt)
IL (1) IL135584A (pt)
NO (1) NO20001869L (pt)
NZ (1) NZ504419A (pt)
PL (1) PL339910A1 (pt)
TR (1) TR200001018T2 (pt)
WO (1) WO1999018794A1 (pt)
ZA (1) ZA989365B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142175A1 (de) * 2001-10-09 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung von ß-Adrenozeptor-Agonisten zur Behandlung von neurodegenerativen Erkrankungen
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1499310A4 (en) * 2002-04-30 2005-12-07 Sb Pharmco Inc MONOCITRATE MONOHYDRATE OF CARVEDILOL
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
MXPA04012923A (es) * 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
CN1991364A (zh) * 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
LT2247558T (lt) 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
CN103172643B (zh) * 2011-12-26 2016-03-02 中国医学科学院药物研究所 黄皮咔唑生物碱及其制备方法和其药物组合物与用途
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
WO2014210544A2 (en) * 2013-06-27 2014-12-31 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
CA3192905A1 (en) * 2020-09-17 2022-06-23 Sui Rong Wayne CHEN Methods of treating and/or preventing alzheimer's disease with r-carvedilol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
IE60991B1 (en) * 1986-12-17 1994-09-07 Glaxo Group Ltd Use of ketone derivatives in the treatment of cognitive disorders
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
JPH0558998A (ja) * 1991-09-06 1993-03-09 Taisho Pharmaceut Co Ltd カルバゾール誘導体
CN1166169A (zh) * 1994-07-27 1997-11-26 三共株式会社 用作毒蕈碱性受体别构效应物的杂环化合物
FR2724933A1 (fr) * 1994-09-22 1996-03-29 Pf Medicament Nouveaux ethers aromatiques derives d'indoles utiles comme medicaments
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JPH11505526A (ja) * 1995-05-01 1999-05-21 ユニヴァーシティ・オヴ・ピッツバーグ アルツハイマー病の死前診断ならびにアミロイド沈着のイン・ビボのイメージ化及び予防のためのアゾ化合物

Also Published As

Publication number Publication date
PL339910A1 (en) 2001-01-15
HUP0100024A3 (en) 2002-12-28
NZ504419A (en) 2002-11-26
NO20001869L (no) 2000-06-14
TR200001018T2 (tr) 2000-08-21
US6358990B1 (en) 2002-03-19
IL135584A0 (en) 2001-05-20
AU751526B2 (en) 2002-08-22
CA2305262A1 (en) 1999-04-22
NO20001869D0 (no) 2000-04-11
EP1024697A1 (en) 2000-08-09
KR100573352B1 (ko) 2006-04-25
AU1089799A (en) 1999-05-03
CN1281334A (zh) 2001-01-24
ZA989365B (en) 1999-04-15
WO1999018794A1 (en) 1999-04-22
KR20010031108A (ko) 2001-04-16
EP1024697A4 (en) 2007-05-02
HUP0100024A2 (hu) 2001-07-30
IL135584A (en) 2005-12-18
JP2001519364A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
BR9814075A (pt) Método de tratamento da doença de alzheimer
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
SE9604786D0 (sv) New compounds
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
BRPI0408784A (pt) método para usar um composto
EA200001175A1 (ru) Бензотиофены, бензофураны и индолы, полезные в лечении устойчивости к инсулину и гипергликемии
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
NO992705L (no) 3-pyridylenantiomere og deres anvendelse som analgetika
NO20052505L (no) Ny bruk av dextran-sulfat
DE60045508D1 (de) Dalda-analoge und ihre verwendung
ATE239474T1 (de) Verwendung von levobupivacain
DE69719931D1 (de) Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
HRP20010584B1 (en) N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
DE69428325D1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten
DE69808440D1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
BR9813641A (pt) "preparados transmucosais de levosimendan"
IL125951A (en) A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
DE69530771D1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophenderivaten zur herstellung eines medikaments zur knochen- und bruchheilung
NO20010984L (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etyl]-4-piperidinmetanol for behandling av sovnforstyrrelser
CA2543986A1 (en) Norepinephrine reuptake inhibitors and methods of using the same
BG106428A (en) Pharmaceutical compositions for treating psoriasis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO 1976 DE 18/11/2008.